Nordic Bioscience Holding A/S Annual Report 2024 Highlights
We are proud to present the highlights from our 2024 Annual Report, marking a year of significant milestones and outstanding performance at Nordic Bioscience. This year also marks our first-time adoption of full IFRS, reflecting our commitment to transparency and global standards.
Access the full 2024 Annual Report here
Scientific Excellence
Our unique expertise in extracellular matrix (ECM) biomarkers continues to drive innovation in R&D services, clinical diagnostics, and drug development.
With over 700 published scientific papers and a broad portfolio of more than 150 biomarkers, we are at the forefront of advancing precision medicine.
Financial Highlights
- Revenue: DKK 527 million, more than doubling the revenue from previous year.
- Net Profit: DKK 171 million.
- Cash and Cash Equivalents: DKK 455 million at year-end.
- Net Cash Inflow from Operating Activities: DKK 380 million.
Business Segments
- R&D Services: Serving over 100 major pharmaceutical and biotechnology companies, our R&D services saw a 39% revenue increase.
- Clinical Diagnostics: Partnering with Roche, we are leveraging validated ECM biomarkers for diagnostic purposes.
- Drug Development: Together with Eli Lilly, we are developing our DACRA molecules, a potential new class of treatment for obesity and other indications.
We want to thank our dedicated colleagues, partners, and clients for their continued support. Together, we are driving earlier disease detection, better patient outcomes, and more effective treatments.
Access the full 2024 Annual Report here
